MicroPhage is focused on improving health worldwide through leadership in rapid bacterial detection and antimicrobial susceptibility testing.

The Company develops and markets diagnostics for the clinical marketplace through the use of its bacteriophage enabling technology, including high performing, easy to use tests for the direct identification of Staphylococcus aureus (S. aureus) and rapid antibiotic testing of methicillin susceptible and resistant S. aureus (MSSA and MRSA).

Our website is under revision. Please excuse the mess as we provide new and exciting content.